...

Journal Options Hepatitis

Course Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, FACP

Browse Journal Options by Topic

View Collections

Featured Expert Commentary

Management of Nonalcoholic Steatohepatitis With Vitamin E

Bruce R. Bacon, MD

Bruce R. Bacon, MD

James F. King, MD, Endowed Chair in Gastroenterology
Professor of Internal Medicine

Division of Gastroenterology and Hepatology
Saint Louis University Liver Center
Saint Louis University School of Medicine
St Louis, Missouri

Recent Articles

  • Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

    Sanyal AJ, Chalasani N, Kowdley KV, et al.

    N Engl J Med. 2010;362:1675-1685.

    Capsule Summary | Expert Commentary | Abstract | Slides

  • Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B.

    Wong VW, Wong GL, Yan KK, et al.

    Hepatology. 2010;51:1945-1953.

    Capsule Summary | Expert Commentary | Abstract | Slides

  • Long-term efficacy of tenofovir monotherapy for hepatitis B virus–monoinfected patients after failure of nucleoside/nucleotide analogues.

    van Bömmel F, de Man RA, Wedemeyer H, et al.

    Hepatology. 2010;51:73-80.

    Capsule Summary | Expert Commentary | Abstract | Slides

  • Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naive, hepatitis B e antigen–positive patients receiving entecavir.

    Jung YK, Kim JH, Lee YS, et al.

    J Clin Gastroenterol. 2010;Epub ahead of print.

    Capsule Summary | Expert Commentary | Abstract | Slides

  • Hepatic interferon-stimulated genes expression is associated with genetic variation in interleukin 28B and the outcome of interferon therapy for chronic hepatitis C.

    Honda M, Sakai A, Yamashita T, et al.

    Gastroenterology. 2010;Epub ahead of print.

    Capsule Summary | Expert Commentary | Abstract | Slides

  • Telaprevir for previously treated chronic HCV infection.

    McHutchison JG, Manns MP, Muir AJ, et al.

    N Engl J Med. 2010;362:1292-1303.

    Capsule Summary | Expert Commentary | Abstract | Slides

  • Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.

    Ferenci P, Laferl H, Scherzer TM, et al.

    Gastroenterology. 2010;138:503-512.

    Capsule Summary | Expert Commentary | Abstract | Slides

  • Rifaximin treatment in hepatic encephalopathy.

    Bass NM, Mullen KD, Sanyal A, et al.

    N Engl J Med. 2010;362:1071-1081.

    Capsule Summary | Expert Commentary | Abstract | Slides

  • Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients.

    Angelico F, Franicoso S, Del Ben M, et al.

    Aliment Pharmacol Ther. 2009;30:444-451.

    Capsule Summary | Expert Commentary | Abstract | Slides

  • Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients.

    Berg T, Weich V, Teuber G, et al.

    Hepatology. 2009;50:369-377.

    Capsule Summary | Expert Commentary | Abstract | Slides

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

Volume 4, Issue 1 Collection

Hepatitis Journal Options – Volume 4, Issue 1 CME



Program Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, FACP

Faculty:

Bruce R. Bacon, MDRobert S. Brown, Jr., MD, MPHMaurizia Rossana Brunetto, MD
  • Bruce R. Bacon, MD
  • Robert S. Brown, Jr., MD, MPH
  • Maurizia Rossana Brunetto, MD
Jordan J. Feld, MD, MPHPaul Martin, MDTimothy Morgan, MD
  • Jordan J. Feld, MD, MPH
  • Paul Martin, MD
  • Timothy Morgan, MD
Paul J. Pockros, MDMark S. Sulkowski, MD
  • Paul J. Pockros, MD
  • Mark S. Sulkowski, MD

Abstract

CREDIT INFORMATION

Release Date: August 31, 2010

Expiration Date: August 30, 2011


Physicians: maximum of 1.0 AMA PRA Category 1 Credit

Status: Please log in to view status

Volume 3, Issue 3 Collection

Hepatitis Journal Options – Volume 3, Issue 3 CME



Program Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, FACP

Faculty:

Natalie H. Bzowej, MD, PhDPeter Ferenci, MDMichael Gale, Jr., PhD
  • Natalie H. Bzowej, MD, PhD
  • Peter Ferenci, MD
  • Michael Gale, Jr., PhD
Stuart C.  Gordon, MDTarek Hassanein, MD, FACP, FACG, AGAFPaul Y.  Kwo, MD
  • Stuart C. Gordon, MD
  • Tarek Hassanein, MD, FACP, FACG, AGAF
  • Paul Y. Kwo, MD
Alessandra Mangia, MDSammy Saab, MD, MPH, AGAF
  • Alessandra Mangia, MD
  • Sammy Saab, MD, MPH, AGAF

CREDIT INFORMATION

Release Date: November 12, 2009

Expiration Date: November 11, 2010


Physicians: maximum of 1.0 AMA PRA Category 1 Credit

Status: Please log in to view status